Status: Not yet recruiting
Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer
This study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with unresectable locally advanced gastric cancer who had not received systemic treatment.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Chen LizhuUpdated: Jun 10, 2026
Eligibility criteria
Provided written informed consent before performing any trial-related procedures... [+6]
Known HER2 positivity; [+26]